Drug Trial Radar · NCT05555706
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Dec 6, 2022
Primary completion
Sep 30, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Pharmaceuticals Holding Co., Ltd
- First posted
- Sep 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
Conditions
- Triple Negative Breast Cancer (TNBC)
Interventions
B013+Nab-PaclitaxelDrug
B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle. Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)(phase Ⅱ)Time frame: Baseline up to approximately 18 months
- Progression-free survival (PFS)(IRC) (phase Ⅲ)Time frame: Baseline up to approximately 18 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, China
Tianjin medical university cancer institute&hospital
Tianjin, China
Affiliated Cancer Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Hainan cancer Hospital
Haikou, Hainan, China
The First Affiliated Hospital of henan University of Science and Technoloy
Luoyang, Henan, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
The Central Hospital of Yongzhou
Yongzhou, Hunan, China
Huai'an First People's Hospital
Huai'an, Jiangsu, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
The second people's hospital of neijiang
Neijiang, Sichuan, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.